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Abstract
Surgery is currently the only curative treatment for patients with cholangiocarcinoma (CCA). Whether histological
diagnosis of CCA is necessary before surgery is controversial. Fifteen percent of patients with suspected biliary malignancy
who undergo surgery are found to have benign disease. Surgery is a major procedure with significant morbidity and
mortality and alternative treatment is available for those known to have benign stenoses. The aim of this review was to
determine whether any of the current diagnostic tests have sufficient sensitivity and specificity to identify patients with
benign and malignant bile duct stenoses. A literature search was performed until July 2007 to obtain information from
studies published in the previous 10 years. Only studies reporting an appropriate reference test (confirmation of malignancy
by biopsy, confirmation of benign nature by histology following surgical excision, or at least 6 months of follow-up for all
patients) were included for review. The diagnostic odds ratio was used to measure diagnostic performance. Forty-one
references of 34 studies were included in this review. None of the studies used differential verification. Six studies used
blinding of assessor. None of the diagnostic tests had sufficient diagnostic accuracy to reliably separate patients with benign
from malignant biliary strictures. Differentiating benign from malignant bile strictures is an important aim. There is no trial
evidence demonstrating benefit in obtaining a preoperative histological diagnosis of CCA. New methods are required for
stricture assessment.
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Background
Cholangiocarcinoma (CCA) may arise from either the
intrahepatic or extrahepatic bile duct, but typically
arises at the bifurcation of the right and left hepatic
ducts (Klatskin’s tumor) [1]. The incidence of CCA
has increased by about 16-fold in the past three
decades [2] and is currently 1.13 and 1.35 per
100,000 males and females in England and Wales
[2]. Surgery is currently the only curative treatment
for patients with CCA [1]. Whether histological
diagnosis of CCA is necessary before surgery is
controversial. The incidence of benign lesions in
patients undergoing surgical resection with suspected
bile duct malignancy is around 15% despite extensive
preoperative assessment [3,4].
Effective treatment without surgery is available for
patients with benign bile duct strictures who can be
treated by progressive endoscopic balloon dilatation
and stenting with success rates reported of 60% to
90% [59]. Surgical intervention remains available for
those in whom endoscopic therapy is not possible or
in whom it fails. As the treatment is radically different,
it is important to establish the benign or malignant
nature of bile duct strictures.
Biopsies taken preoperatively from the site of the
bile duct stricture at endoscopic retrograde cholan-
giopancreatography (ERCP), percutaneous transhe-
patic cholangiography (PTC), or via cholangioscopy
and examined histologically can reliably distinguish
benign from malignant strictures [1012]. However,
taking biopsies of the biliary tract is not without risk.
Tumor seeding after CCA biopsy is recognized, but
has largely been reported after percutaneous transhe-
patic biliary drainage (PTBD) [13,14]. Tumor seed-
ing after a single pass of a biopsy needle has been
reported in hepatocellular carcinomas [13]. Partly
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due to the risk of seeding, tumor biopsy in patients
with potentially resectable CCA in current clinical
guidelines is not recommended [1]. Other complica-
tions of biopsy include bleeding (4.2%), transient
hemobilia and pain (12.5%) [15].
Current review
The current published literature has been reviewed to
assess the ability of preoperative diagnostic tests
available for the assessment of patients with bile
duct strictures to differentiate benign from malignant
strictures. Only studies in which an adequate refer-
ence test was used were included (confirmation of
malignancy by biopsy, confirmation of benign nature
by surgical excision biopsy, or at least 6 months of
follow-up for all patients). The range of sensitivities
and specificities was calculated for each diagnostic
test. The diagnostic odds ratio (DOR) was then
calculated for each modality of investigation by the
method of Deeks [16]. Results are given in Table I.
Results
As indicated in Table I, there was a wide range of
sensitivities between the diagnostic tests as well as a
wide variation reported between different studies
reporting the same investigation. Specificities ranged
from 0% to 100%, again with a very wide variation
between studies using the same diagnostic test. The
best diagnostic odds ratio was seen for CT scan. For
PSC, the highest DOR was seen in a study on PET
scanning. However, two other studies on PET scan-
ning showed poor DOR. None of the diagnostic
modalities had consistently high accuracy for the
investigation to be recommended as the diagnostic
modality of choice, i.e. there is no Grade A recom-
mendation (recommendation based on direct scien-
tific fact) for any of the diagnostic modalities used.
Discussion
Assessment of the diagnostic tests evaluated in this
analysis has focused solely on their ability to separate
patients with benign from malignant biliary strictures.
Clearly, these investigations provide information on
many other aspects, including the stage of disease and
whether a malignant bile duct stricture may be related
to CCA rather than HCC, pancreatic Ca or meta-
static nodal disease. The ability of the test to
distinguish between the different malignancies of the
biliary tract was not reported in the studies.
In patients with a malignant bile duct stricture,
there is currently no evidence for the benefit of neo-
adjuvant therapy [4042]. The decision to operate
may therefore be unaltered by whether the malignant
stricture is secondary to CCA, HCC, or pancreatic
cancer. However, a preoperative diagnosis of meta-
static disease would completely alter the treatment
plan. The incidence of metastatic disease producing
bile duct obstruction with features suggestive of bile
duct cancer is 1% to 9% of biliary strictures [20,43].
The diagnostic tests assessed in this review carried a
poor diagnostic ability. Histological assessment of
biopsies from the stricture site has variable sensitivity
(52% to 93%) [1012,44,45], although it is highly
specific [11,12,45]. The main reasons for the variable
sensitivity of biopsies are: (a) the type of lesions (i.e.
polypoid versus stenotic) and (b) the number of
biopsies [46]. While a positive tissue diagnosis is
confirmatory of cancer (high specificity) [11,12,45], a
negative result does not rule out cancer. Surgical
Table I. Diagnostic performance.
Diagnostic test Sensitivity (range) Specificity (range) Diagnostic odds ratio (range)
ERCP [1719] 0.0 to 0.66 0.61 to 1 0 to 165
ERCP FNA [20] 0.45 1 4
EUS [21] 0.76 0.75 8
EUS FNA [22,23] 0.62 to 0.86 0.88 to 1 26 to 36
IDUS [21,24,25] 0.89 to 0.91 0.5 to 0.93 7 to 90
Cholangioscopy [18,19] 0.92 to 1 0.51 to 0.91 8 to 786
Brush cytology (ERCP) [20,26,27] 0.2 to 0.85 0.67 to 1 4 to 59
Bile cytology (PTC) [24,28] 0.43 to 0.64 0.93 to 1 16 to 35
DNA ploidy [17,26,29] 0.29 to 0.85 0.91 to 1 3 to 75
Molecular markers in brush cytology [30,31] 0.17 to 1 0.79 to 1 3 to 31
Molecular markers in bile [32] 0.33 to 0.67 1 7 to 23
Serum Ca 199 [17,33] 0.54 to 1 0.4 to 0.9 2 to 14
Serum CEA [17] 0.56 0.89 9
Biliary Ca 19-9 [17] 0.46 0.70 2
Biliary CEA [17] 0.58 0.8 6
CT scan [34,35] 0.94 to 1 0.83 to 0.92 54 to 192
MRCP [36] 1 0.14 Not available
PET scan [3739] 0.5 to 1 0 to 1 1 to 247
CTcomputed tomogram, DNAdeoxyribonucleic acid, ERCPendoscopic retrograde cholangiopancreatography, EUSendoscopic
ultrasound, FNAfine-needle aspiration, IDUSintraductal sonography, PETpositron emission tomography, PTCpercutaneous
transhepatic cholangiography.
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excision would therefore be the best option for a
lesion highly suspicious of a cancer on radiology with
a negative tissue diagnosis.
New techniques are clearly required to improve our
ability to detect and determine the nature of a biliary
tract cancer in patients presenting with a bile duct
stricture. Optical coherence tomography (OCT or
optical biopsy) is a method similar to intraductal
ultrasound but uses infrared light rather than sound to
provide the image [47]. It provides tissue architecture
which could previously be obtained only by conven-
tional biopsy [47]. Preliminary results suggest that the
addition of OCT improves the diagnostic accuracy of
biliary brushings [48]. Magnetic resonance spectro-
scopy (MRS) provides non-invasive information on
phospholipid metabolism [49]. The levels of phos-
phatidyl choline in bile are lower in cancer patients
compared to controls [49]. Further assessment of
whether this can be used for diagnostic purposes is
necessary.
The use of a DNA microarray for gene profiling
using a set of genes common to many malignancies
has been reported with a variety of cancer types [50]
and may lead to detection of a cancer type from blood
without the need for a histological diagnosis [51].
Conclusions
. None of the currently available tests (including
histological examination of biopsy specimens)
can reliably distinguish benign from malignant
biliary strictures.
. The evidence for the diagnostic ability of the tests
is based on case-control or cohort studies with
high risk of bias.
. There is currently no evidence to support routine
histological examination for the diagnosis of
CCA.
. Randomized controlled trials assessing the need
for routine histological diagnosis in the preopera-
tive diagnosis of CCA should follow the consort
statement [52] and be adequately powered.
. Based on detecting a 10% reduction in the
requirement for unnecessary surgery, sample
size calculation (performed using statistical soft-
ware StatsDirect version 2.6.7) revealed that for
a0.05 (two tailed) and a statistical power of 0.8
at least 282 patients would be needed. This is
feasible only as a multicentric trial.
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